Europe Mid-Size Pharmaceutical Market Forecast to 2028 – COVID

Europe Mid-Size Pharmaceutical Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Prescription and Over-the-Counter), Drug Development Type (In-House and Outsource), Formulation (Tablets and Capsules, Injectables, Sprays, and Other Formulations), and Therapy Class (Cardiovascular Diseases, Pain Management, Diabetes, Cancer, and Other Conditions)

Report Code : BMIRE00026179 | Region : Europe | Industry : Pharmaceuticals | Published Date : 23/Sep/2022

The mid-size pharmaceutical market in Europe is expected to grow from US$ 201,707.89 million in 2022 to US$ 288,168.27 million by 2028; it is estimated to grow at a CAGR of 6.1% from 2022 to 2028.

The mid-size pharmaceutical market in Europe is characterized by the presence of various market players. To increase their market share, the players adopt various strategies such as product launches, regional expansion, and technological advancements. Leading players invest in R&D to develop advanced technologies and gain revenue. Europe accounts for the second-largest market share and is anticipated to register a significant growth rate over the forecast period. The market growth in this region is attributed to the increasing number of product launches and the growing prevalence of chronic diseases. Further, increased government expenditures on the healthcare sector favor the entry of new players in the mid-size pharmaceutical market in this region. However, the cutthroat competition among market players hinders the market growth.

By introducing new features and technologies, vendors in the Europe mid-size pharmaceutical market can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the market growth at a good CAGR during the forecast period.

Europe Mid-Size Pharmaceutical Market Revenue and Forecast to 2028 (US$ Million)

Europe Mid-Size Pharmaceutical Market Segmentation

The Europe mid-size pharmaceutical market is segmented on the basis of type, drug development type, formulation, therapy class, and country.

Based on type, the Europe mid-size pharmaceutical market is bifurcated into prescription and over-the-counter. In 2022, the over-the-counter segment accounted for a larger market share. Based on drug development type, the market is bifurcated into in-house and outsource. The outsource segment held a larger market share in 2022. Based on formulation, the Europe mid-size pharmaceutical market is segmented into tablets and capsules, injectables, sprays, and other formulations. The tablets & capsules segment held the largest market share in 2022. Based on therapy class, the market is segmented into cardiovascular diseases, pain management, diabetes, cancer, and other conditions. The diabetes segment held the largest market share in 2022. Based on country, the Europe mid-size pharmaceutical market is segmented into Germany, France, the UK, Italy, Spain, and Rest of Europe. Germany held the largest market share in 2022.

Alexion Pharmaceuticals, Inc.; Bausch Health Companies Inc.; Daiichi Sankyo Company Limited; Eisai Co., Ltd.; Endo Pharmaceuticals Inc.; Les Laboratories Servier; Mallinckrodt; Regeneron Pharmaceuticals, Inc; Sun Pharmaceutical Industries Ltd; and UCB S.A. are among the leading companies operating in the mid-size pharmaceutical market in the region.

At 6.1% CAGR, the Europe Mid-Size Pharmaceutical Market market is speculated to be worth US$ 2,88,168.27 Million by 2028, says The Insight Partners

According to The Insight Partners’ research, the Europe mid-size pharmaceutical market market was valued at US$ 2,01,707.89 million in 2022 and is expected to reach US$ 4,61,269.34 million by 2028, registering an annual growth rate of 6.7% from 2022 to 2028. Rising prevalence of chronic disorders and benefits of the mid-size pharmaceutical market are the critical factors attributed to the market expansion.

The aging population and changes in social behavior contribute to the steady increase in these common and costly long-term health problems. With the accelerating urbanization, people are adopting a more sedentary lifestyle. This boosts obesity rates and cases of illnesses such as diabetes. Emerging markets will be hit hardest, as population growth is expected to be the strongest in developing countries. Increasing demand for health care systems due to chronic illnesses has become a major concern.

Diabetes is one of the biggest health problems of the 21st century. Every year, more and more people develop this condition, causing life-changing complications. The increase in disease prevalence is about 35% over the predicted period. The Pandemics have tested the rate at which infections unfold throughout the globe. Pandemics exert periodic and enormous disruptive strains on fitness systems. Healthcare establishments throughout the globe want to be geared up to collectively comprise outbreaks once they occur. Thus, the increasing prevalence of chronic disorders boosts the mid-size pharmaceutical market.

On the contrary, high competition among market players hurdles the growth of Europe mid-size pharmaceutical market market.

Based on type, the Europe mid-size pharmaceutical market is bifurcated into prescription and over-the-counter. The over-the-counter segment holds 63.2% market share in 2022, amassing US$ 1,27,473.81 million. It is projected to garner US$ 1,85,191.34 million by 2028 to expand at 6.4% CAGR during 2022–2028.

Based on drug development type, the Europe mid-size pharmaceutical market is bifurcated into in-house and outsource. The outsource segment holds 88.9% market share in 2022, amassing US$ 1,79,236.23 million. It is projected to garner US$ 2,61,233.78 million by 2028 to expand at 6.5% CAGR during 2022–2028.

Based on formulation, the Europe mid-size pharmaceutical market is segmented into tablets and capsules, injectables, sprays, and other formulations. With 35.8% share of the domain, the tablets and capsules segment dominates the market in 2022. It accrued US$ 72,145.95 million in 2022 and is estimated to generate US$ 1,07,189.07 million by 2028 to grow at a CAGR of 6.8% over the forecast period.

By therapy class, the Europe mid-size pharmaceutical market is segmented into cardiovascular diseases, pain management, diabetes, cancer, and other conditions. With 34.0% share of the domain, the diabetes segment dominates the market in 2022. It accrued US$ 68,634.66 million in 2022 and is estimated to generate US$ 99,259.92 million by 2028 to grow at a CAGR of 6.3% over the forecast period.

Our regional analysis states that Germany captured 27.4% market share in 2022. It is assessed at US$ 55,288.13 million in 2022 and is likely to hit US$ 82,300.86 million by 2028, exhibiting a CAGR of 6.9% during the forecast period.

Key players dominating the Europe mid-size pharmaceutical market market are Alexion Pharmaceuticals, Inc.; Bausch Health Companies Inc.; Daiichi Sankyo Company Limited; Eisai Co., Ltd.; Endo Pharmaceuticals Inc.; Les Laboratories Servier; Mallinckrodt; Regeneron Pharmaceuticals, Inc; Sun Pharmaceutical Industries Ltd; and UCB S.A. among others.

A few major key developments among the top market players are described below:

In April 2022, Regeneron Pharmaceuticals, Inc. and Checkmate Pharmaceuticals, Inc. announced a definitive agreement for Regeneron to acquire Checkmate for $10.50 per share of Checkmate common stock in an all-cash transaction. Checkmate's entire stock value is estimated to be around $250 million in the proposed acquisition. Contact Us

Contact Person: Sameer Joshi

Phone: +1- 646- 491- 9876

Email id: [email protected]

TABLE OF CONTENTS

1. Introduction

1.1 Scope of the Study

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 Europe Mid-Size Pharmaceutical – By Type

1.3.2 Europe Mid-Size Pharmaceutical – By Drug Development Type

1.3.3 Europe Mid-Size Pharmaceutical – By Formulation

1.3.4 Europe Mid-Size Pharmaceutical – By Therapy Area

1.3.5 Europe Mid-Size Pharmaceutical – By Country

2. Mid-Size Pharmaceutical– Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. Europe Mid-Size Pharmaceutical – Market Landscape

4.1 Overview

4.2 Europe PEST Analysis

4.3 Expert Opinion

5. Mid-Size Pharmaceutical Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Increasing Prevalence of Chronic Disorders

5.1.2 Increasing Product Approval and Launches

5.2 Market Restraints

5.2.1 Cutthroat Competition among Market Players

5.3 Market Opportunities

5.3.1 Rising Number of Healthcare Start-ups

5.4 Future Trends

5.4.1 Greater Focus on R&D

5.5 Impact Analysis

6. Mid-Size Pharmaceutical Market– Europe Analysis

6.1 Europe Mid-Size Pharmaceutical Market Revenue Forecast and Analysis

7. Europe Mid-Size Pharmaceutical Market Revenue and Forecasts To 2028– by Type

7.1 Overview

7.2 Europe Mid-Size Pharmaceutical Market Revenue Share, by Type (2022 and 2028)

7.3 Prescription

7.3.1 Overview

7.3.2 Prescription: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

7.4 Over-the-Counter (OTC)

7.4.1 Overview

7.4.2 Over-the-Counter: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

8. Europe Mid-Size Pharmaceutical Market Analysis – By Drug Development Type

8.1 Overview

8.2 Europe Mid-Size Pharmaceutical Market Revenue Share, by Drug Development Type (2022 and 2028)

8.3 In-House

8.3.1 Overview

8.3.2 In-House: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

8.4 Outsource

8.4.1 Overview

8.4.2 Outsource: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

9. Europe Mid-Size Pharmaceutical Market – By Formulation

9.1 Overview

9.2 Europe Mid-Size Pharmaceutical Market, by Formulation, 2022 and 2028 (%)

9.3 Tablets and Capsules

9.3.1 Overview

9.3.2 Tablets and Capsules: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

9.4 Injectables

9.4.1 Overview

9.4.2 Injectables: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

9.5 Sprays

9.5.1 Overview

9.5.2 Sprays: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

9.6 Other Formulations

9.6.1 Overview

9.6.2 Others: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

10. Europe Mid-Size Pharmaceutical Market – By Therapy Class

10.1 Overview

10.2 Europe Mid-Size Pharmaceutical Market, by Therapy Class, 2022 and 2028 (%)

10.3 Cardiovascular Diseases

10.3.1 Overview

10.3.2 Cardiovascular Diseases: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

10.4 Pain Management

10.4.1 Overview

10.4.2 Pain Management: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

10.5 Diabetes

10.5.1 Overview

10.5.2 Diabetes: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

10.6 Cancer

10.6.1 Overview

10.6.2 Cancer: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

10.7 Other Diseases

10.7.1 Overview

10.7.2 Other Diseases: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

11. Europe Mid-Size Pharmaceutical Market Revenue and Forecasts to 2028 – Country Analysis

11.1 Overview

11.1.1 Europe: Mid-Size Pharmaceutical Market, by Country, 2021 & 2028 (%)

11.1.1.1 Germany: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.1.1 Overview

11.1.1.1.2 Germany: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.1.3 Germany: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)

11.1.1.1.4 Germany: Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)

11.1.1.1.5 Germany: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)

11.1.1.1.6 Germany: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)

11.1.1.2 France: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.2.1 Overview

11.1.1.2.2 France: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.2.3 France: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)

11.1.1.2.4 France: Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)

11.1.1.2.5 France: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)

11.1.1.2.6 France: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)

11.1.1.3 UK: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.3.1 Overview

11.1.1.3.2 UK: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.3.3 UK: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)

11.1.1.3.4 UK: Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)

11.1.1.3.5 UK: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)

11.1.1.3.6 UK: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)

11.1.1.4 Italy: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.4.1 Overview

11.1.1.4.2 Italy: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.4.3 Italy: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)

11.1.1.4.4 Italy: Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)

11.1.1.4.5 Italy: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)

11.1.1.4.6 Italy: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)

11.1.1.5 Spain: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.5.1 Overview

11.1.1.5.2 Spain: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.5.3 Spain: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)

11.1.1.5.4 Spain: Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)

11.1.1.5.5 Spain: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)

11.1.1.5.6 Spain: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)

11.1.1.6 Rest of Europe: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.6.1 Overview

11.1.1.6.2 Rest of Europe: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

11.1.1.6.3 Rest of Europe: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)

11.1.1.6.4 Rest of Europe: Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)

11.1.1.6.5 Rest of Europe: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)

11.1.1.6.6 Rest of Europe: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)

12. Mid-Size Pharmaceutical Market–Industry Landscape

12.1 Overview

12.2 Growth Strategies Done by the Companies in the Market, (%)

12.3 Organic Developments

12.3.1 Overview

12.4 Inorganic Developments

12.4.1 Overview

13. Company Profiles

13.1 DAIICHI SANKYO COMPANY LIMITED

13.1.1 Key Facts

13.1.2 Business Description

13.1.3 Products and Services

13.1.4 Financial Overview

13.1.5 SWOT Analysis

13.1.6 Key Developments

13.2 Eisai Co., Ltd.

13.2.1 Key Facts

13.2.2 Business Description

13.2.3 Products and Services

13.2.4 Financial Overview

13.2.5 SWOT Analysis

13.2.6 Key Developments

13.3 Bausch Health Companies Inc.

13.3.1 Key Facts

13.3.2 Business Description

13.3.3 Products and Services

13.3.4 Financial Overview

13.3.5 SWOT Analysis

13.3.6 Key Developments

13.4 Regeneron Pharmaceuticals, Inc

13.4.1 Key Facts

13.4.2 Business Description

13.4.3 Products and Services

13.4.4 Financial Overview

13.4.5 SWOT Analysis

13.4.6 Key Developments

13.5 Sun Pharmaceutical Industries Ltd

13.5.1 Key Facts

13.5.2 Business Description

13.5.3 Products and Services

13.5.4 Financial Overview

13.5.5 SWOT Analysis

13.5.6 Key Developments

13.6 Alexion Pharmaceuticals, Inc.

13.6.1 Key Facts

13.6.2 Business Description

13.6.3 Products and Services

13.6.4 Financial Overview

13.6.5 SWOT Analysis

13.6.6 Key Developments

13.7 Mallinckrodt

13.7.1 Key Facts

13.7.2 Business Description

13.7.3 Products and Services

13.7.4 Financial Overview

13.7.5 SWOT Analysis

13.7.6 Key Developments

13.8 Endo Pharmaceuticals Inc.

13.8.1 Key Facts

13.8.2 Business Description

13.8.3 Products and Services

13.8.4 Financial Overview

13.8.5 SWOT Analysis

13.8.6 Key Developments

13.9 Les Laboratories Servier

13.9.1 Key Facts

13.9.2 Business Description

13.9.3 Products and Services

13.9.4 Financial Overview

13.9.5 SWOT Analysis

13.9.6 Key Developments

13.10 UCB S.A.

13.10.1 Key Facts

13.10.2 Business Description

13.10.3 Products and Services

13.10.4 Financial Overview

13.10.5 SWOT Analysis

13.10.6 Key Developments

14. Appendix

14.1 About The Insight Partners

14.2 Glossary of Terms

LIST OF TABLES.

Table 1.             Germany: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 2.             Germany: Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)

Table 3.             Germany: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)

Table 4.             Germany: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)

Table 5.             France: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 6.             France: Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)

Table 7.             France: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)

Table 8.             France: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)

Table 9.             UK: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 10.          UK: Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)

Table 11.          UK: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)

Table 12.          UK: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)

Table 13.          Italy: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 14.          Italy: Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)

Table 15.          Italy: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)

Table 16.          Italy: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)

Table 17.          Spain: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 18.          Spain: Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)

Table 19.          Spain: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)

Table 20.          Spain: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)

Table 21.          Rest of Europe: Mid-Size Pharmaceutical Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 22.          Rest of Europe: Mid-Size Pharmaceutical Market, by Drug Development Type– Revenue and Forecast to 2028 (US$ Million)

Table 23.          Rest of Europe: Mid-Size Pharmaceutical Market, by Formulation – Revenue and Forecast to 2028 (US$ Million)

Table 24.          Rest of Europe: Mid-Size Pharmaceutical Market, by Therapy Area – Revenue and Forecast to 2028 (US$ Million)

Table 25.          Organic Developments Done By Companies

Table 26.          Inorganic Developments Done By Companies

Table 27.          Glossary of Terms

LIST OF FIGURES.

Figure 1.           Europe Mid-Size Pharmaceutical Segmentation

Figure 2.           Europe Mid-Size Pharmaceutical Segmentation, By Country

Figure 3.           Europe Mid-Size Pharmaceutical Overview

Figure 4.           Over-the-Counter Segment Held Largest Share by Type in Europe Mid-Size Pharmaceutical Market

Figure 5.           Germany Is Expected to Show Remarkable Growth During the Forecast Period

Figure 6.           Europe: PEST Analysis

Figure 7.           Europe Mid-Size Pharmaceutical Market– Revenue Forecast And Analysis – 2020- 2028

Figure 8.           Europe Mid-Size Pharmaceutical Market Revenue Share, by Type (2022 and 2028)

Figure 9.           Europe Prescription: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 10.        Europe Over-the-Counter: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 11.        Europe Mid-Size Pharmaceutical Market Revenue Share, by Drug Development Type (2022 and 2028)

Figure 12.        Europe In-House: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 13.        Europe Outsource: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 14.        Europe Mid-Size Pharmaceutical Market, by Formulation, 2022 and 2028 (%)

Figure 15.        Europe Tablets and Capsules: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 16.        Europe Injectables: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 17.        Europe Sprays: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 18.        Europe Others: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 19.        Europe Mid-Size Pharmaceutical Market, by Therapy Class, 2022 and 2028 (%)

Figure 20.        Europe Cardiovascular Diseases: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 21.        Europe Pain Management: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 22.        Europe Diabetes: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 23.        Europe Cancer: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 24.        Europe Other Diseases: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 25.        Europe: Mid-Size Pharmaceutical Market, by Key Country – Revenue (2021) (US$ Million)

Figure 26.        Europe: Mid-Size Pharmaceutical Market, by Country, 2021 & 2028 (%)

Figure 27.        Percentage of people aged 65+ reporting chronic diseases are as follows: (Source: European Commission (2019a), Joint report on health care)

Figure 28.        Germany: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 29.        France: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 30.        UK: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 31.        Italy: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 32.        Spain: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 33.        Rest of Europe: Mid-Size Pharmaceutical Market – Revenue and Forecast to 2028 (US$ Million)

Figure 34.        Growth Strategies Done by the Companies in the Market, (%)

The List of Companies - Europe Mid-Size Pharmaceutical Market

● Alexion Pharmaceuticals, Inc.

● Bausch Health Companies Inc.

● Daiichi Sankyo Company Limited

● Eisai Co., Ltd.

● Endo Pharmaceuticals Inc.

● Les Laboratories Servier

● Mallinckrodt

● Regeneron Pharmaceuticals, Inc

● Sun Pharmaceutical Industries Ltd

● UCB S.A.

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Europe mid-size pharmaceutical market

● Highlights key business priorities in order to assist companies to realign their business strategies

● The key findings and recommendations highlight crucial progressive industry trends in the Europe mid-size pharmaceutical market, thereby allowing players across the value chain to develop effective long-term strategies

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets

● Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the mid-size pharmaceutical market, as well as those hindering it

● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing and distribution

TOP